Canadian recommendations for the treatment of glioblastoma multiforme

Cancer research · Diffuse large B-cell lymphoma · EGFR · TP53

Management of patients with glioblastoma multiforme (gbm) should be highly individualized and should take a multidisciplinary approach involving neuro‑oncology, neurosurgery, radiation oncology, and pathology, to optimize treatment outcomes.

The Canadian GBM Recommendations Committee provides evidence‑based guidance on the multidimensional management of glioblastoma multiforme (GBM), with particular emphasis on maximal safe resection, postoperative external‑beam radiotherapy (60 Gy in 2‑Gy fractions), concomitant temozolomide (75 mg/m²/day for 42 days), and adjuvant temozolomide (150–200 mg/m² 5/28‑day schedule for up to 6 cycles). The recommendations highlight the prognostic value of MGMT promoter methylation and encourage detailed cytogenetic and molecular profiling.

Differentiating patient‑specific factors and integrating molecular markers such as MGMT promoter methylation or EGFR status allows clinicians to tailor therapy (e.g., dose intensity, radiotherapy duration, and adjuvant temozolomide schedule) to maximize survival and minimize unnecessary toxicity in GBM patients. This guidance directly impacts clinical decision‑making and resource allocation in neuro‑oncology practice.

Evidence level: Feltételezés / hírjelzés. Nincs önálló tudományos bizonyíték.

Original source

Related signals